TX 103
Alternative Names: TX-103Latest Information Update: 29 Jul 2024
At a glance
- Originator Fuzhou Tcelltech Biological Science and Technology; Tcelltech Inc.
- Developer Fuzhou Tcelltech Biological Science and Technology
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Glioblastoma
Most Recent Events
- 01 Jul 2024 Tcelltech plans a phase I trial for Glioma (Late-stage disease, Second-line therapy or greater) in China (intraventricular, Injection) (NCT06482905) (ChiCTR2400086477)
- 30 Jun 2024 Efficacy, pharmacodynamics and adverse events data from the phase I trial in Glioblastoma presented at the 60th Annual Meeting of American society of clinical oncology (ASCO-2024)
- 30 Jan 2024 Fuzhou Tuoxin Tiancheng Biotechnology plans a phase I trial for Solid tumours (late-stage disease, Second-line therapy or greater) in China (Iv, Infusion) (CTR20240273)